UTHR as reported
United Therapeutics Corporation reported $3.17B of revenue over the trailing twelve months, +5.9% on the year before. 11 reported series are charted on this page, each one as filed.
$3.17B
Revenue, trailing twelve months · to Q1 2026 · +5.9% against the twelve months before
- Net Income
- $1.29B
Net Income · +6.3% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $1.02B
Free Cash Flow · −9.9% year on year · trailing twelve months to Q1 2026
- Op Margin
- 45%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.17B | +5.9% | Q1 2026 |
| Net Income | $1.29B | +6.3% | Q1 2026 |
| EPS | $27.08 | +8.0% | Q1 2026 |
| Gross Margin | 87% | n/a | Q1 2026 |
| Op Margin | 45% | n/a | Q1 2026 |
| Net Margin | 41% | n/a | Q1 2026 |
| ROE | 19% | n/a | Q1 2026 |
| ROA | 17% | n/a | Q1 2026 |
| ROIC | 29% | n/a | Q4 2025 |
| Free Cash Flow | $1.02B | −9.9% | Q1 2026 |
| P/E | 19.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
United Therapeutics Corporation (UTHR) - Revenue & ProfitRevenue & ProfitUnited Therapeutics Corporation (UTHR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #6 of 28 by Smart Score